FDA is misapplying tools meant to speed rare disease cures

A patient advocate argues that the FDA is misapplying the platform technology designation, a tool intended to accelerate drug development for rare diseases. The author claims that inconsistent regulatory flexibility is creating uncertainty and delaying life-saving treatments.